Market capitalization | $78.76b |
Enterprise Value | $71.66b |
P/E (TTM) P/E ratio | 17.73 |
EV/FCF (TTM) EV/FCF | 20.83 |
EV/Sales (TTM) EV/Sales | 5.18 |
P/S ratio (TTM) P/S ratio | 5.69 |
P/B ratio (TTM) P/B ratio | 2.69 |
Revenue growth (TTM) Revenue growth | 5.72% |
Revenue (TTM) Revenue | $13.85b |
Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
28 Analysts have issued a Regeneron Pharmaceuticals forecast:
28 Analysts have issued a Regeneron Pharmaceuticals forecast:
Sep '24 |
+/-
%
|
||
Revenue | 13,847 13,847 |
6%
6%
|
|
Gross Profit | 11,456 11,456 |
4%
4%
|
|
EBITDA | 4,608 4,608 |
7%
7%
|
EBIT (Operating Income) EBIT | 4,138 4,138 |
9%
9%
|
Net Profit | 4,655 4,655 |
17%
17%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.
Head office | United States |
CEO | Leonard Schleifer |
Employees | 13,450 |
Founded | 1988 |
Website | www.regeneron.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.